Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors

February 1, 2024

https://www.prnewswire.com/news-releases/graviton-bioscience-announces-strategic-investment-from-sanofi-to-advance-development-of-the-next-generation-of-selective-rock2-inhibitors-302049773.html

NEW YORK, Feb. 1, 2024 /PRNewswire/ — Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), along with other therapeutic compounds, announces a strategic investment from Sanofi. Under the terms of the agreement, Sanofi receives a right of first negotiation to license compounds across various indications, including immunological and metabolic syndrome indications, driving the momentum behind ROCK2 inhibitor treatments.

Read more at prnewswire.com

Related news for (MGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.